Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : ajtj's Post-Lobotomy Market Charts and Thoughts -- Ignore unavailable to you. Want to Upgrade?

To: skier31 who wrote (83153)	12/8/2023 4:32:59 PM
From: Qone0	3 Recommendations Recommended By ajtj99 bull_dozer skier31 Read Replies (1) \| Respond to of 97137

They are going to need a new drug now. No telling how low it will go before they get a new drug. I suspect there will be reverse split so they can sell that self offering. Shares of Bluebird bio fell after the company's sickle-cell disease treatment received a black-box warning and was announced at a higher price point than a competitor's treatment. The stock was down 41% to $2.84 on Friday. Shares are down 60% this year. The company's Lyfgenia was approved by the Food and Drug Administration for the treatment of sickle-cell disease. The FDA also approved Casgevy, a sickle-cell treatment developed by Vertex Pharmaceuticals and CRISPR Therapeutics using Crispr gene-modification technology. The FDA said that Lyfgenia would include a black-box warning related to certain cases of blood cancer in patients treated with the drug. Bluebird said the treatment would come with a $3.1 million price tag, compared with the $2.2 million price for Casgevy.